SCHEMBL16372319

SCHEMBL16372319

CC(=O)N[C@H]1CC[C@H]1c1ccc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 4/20 0.49
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CNR1 P21554 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ AGTR1 P30556 1/20 0.40
▸ HTR2A P28223 1/20 0.40
▸ HTR2C P28335 1/20 0.40
▸ HTR2B P41595 1/20 0.40
▸ TAS1R3 Q7RTX0 1/20 0.40
▸ TAS1R1 Q7RTX1 1/20 0.40
▸ TAS1R2 Q8TE23 1/20 0.40
▸ PGR P06401 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30477654 1.00 DPP4 (0.49) DPP4MEN1KMT2ACNR1GAA
SCHEMBL27441418 1.00 DPP4 (0.49) DPP4MEN1KMT2ACNR1GAA
SCHEMBL17806038 1.00 DPP4 (0.49) DPP4MEN1KMT2ACNR1GAA
SCHEMBL22437488 1.00 DPP4 (0.49) DPP4MEN1KMT2ACNR1GAA
SCHEMBL20298536 0.86 HPGD (0.46) HTR2AHTR2CHTR2BHPGDSMN1; SMN2
SCHEMBL19771726 0.85 DPP4 (0.46) DPP4MEN1KMT2ACNR1GAA
SCHEMBL19771727 0.85 DPP4 (0.46) DPP4MEN1KMT2ACNR1GAA
SCHEMBL17799764 0.82 TAS1R3 (0.52) DPP4MEN1KMT2ACNR1GAA
SCHEMBL16220951 0.81 L3MBTL1 (0.57) MEN1KMT2ATAS1R3TAS1R1TAS1R2
SCHEMBL17799743 0.80 SLC6A12 (0.47) TAS1R3TAS1R1TAS1R2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710422-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES SYNGENTA CROP PROTECTION AG (CH) 2026-01-07 — — EP disclosed
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
CN-111417618-B Process for preparing enantiomerically and diastereomerically enriched cyclobutane amines and amides 先正达参股股份有限公司 2023-06-30 — — CN disclosed
US-11053188-B2 Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides SYNGENTA PARTICIPATIONS AG (CH) 2021-07-06 — — US disclosed
US-20200407311-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2020-12-31 — — US disclosed
EP-3710422-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES Syngenta Participations AG (CH) 2020-09-23 — — EP disclosed
CN-111417618-A Process for preparing enantiomerically and diastereomerically enriched cyclobutaneamines and cyclobutaneamides 先正达参股股份有限公司 2020-07-14 — — CN disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed
EP-3019476-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES Syngenta Participations AG (CH) 2016-05-18 — — EP disclosed
WO-2015003951-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS DPP4 625/4885MEN1 2987/4885KMT2A 1918/4885
US-20200407311-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES TBCB, ADORA2B, ADRA2B DPP4 4089/4885MEN1 2245/4885KMT2A 1762/4885
US-11053188-B2 Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides TBCB, ADORA2B, CCNB3 DPP4 4153/4885MEN1 2176/4885KMT2A 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback